RepliCel Life Sciences Valeur d'entreprise
Quel est le Valeur d'entreprise de RepliCel Life Sciences?
Le Valeur d'entreprise de RepliCel Life Sciences, Inc. est $2.79M
Quelle est la définition de Valeur d'entreprise?
La valeur d'entreprise est une mesure de la valeur marchande totale d'une entreprise. Il correspond à la capitalisation boursière avec la dette, les intérêts minoritaires et les actions privilégiées moins la trésorerie et les équivalents de trésorerie totaux.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Valeur d'entreprise des entreprises dans Health Care secteur sur TSXV par rapport à RepliCel Life Sciences
Que fait RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Entreprises avec valeur d'entreprise similaire à RepliCel Life Sciences
- 21 St Century Manag a Valeur d'entreprise de $2.78M
- New Tech Minerals a Valeur d'entreprise de $2.78M
- G Medical Innovations a Valeur d'entreprise de $2.78M
- Kollakorn a Valeur d'entreprise de $2.78M
- MinKap Resources a Valeur d'entreprise de $2.78M
- Home Bistro a Valeur d'entreprise de $2.78M
- RepliCel Life Sciences a Valeur d'entreprise de $2.79M
- KORE Mining a Valeur d'entreprise de $2.79M
- Emu NL a Valeur d'entreprise de $2.79M
- Prospex Oil And Gas Plc a Valeur d'entreprise de $2.80M
- Darshan Orna a Valeur d'entreprise de $2.80M
- Nickel Rock Resources a Valeur d'entreprise de $2.80M
- Delta Drone SA a Valeur d'entreprise de $2.80M